Apellis Pharmaceuticals Inc. (APLS) and Immunomedics Inc. (NASDAQ:IMMU) Comparison side by side

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and Immunomedics Inc. (NASDAQ:IMMU) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apellis Pharmaceuticals Inc. 22 0.00 N/A -2.77 0.00
Immunomedics Inc. 15 -2877.46 N/A -1.62 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 shows Apellis Pharmaceuticals Inc. and Immunomedics Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals Inc. 0.00% -77.1% -60.8%
Immunomedics Inc. 0.00% -121.3% -63.3%

Analyst Ratings

In next table is shown Apellis Pharmaceuticals Inc. and Immunomedics Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Apellis Pharmaceuticals Inc. 0 0 1 3.00
Immunomedics Inc. 0 0 4 3.00

The average price target of Apellis Pharmaceuticals Inc. is $45, with potential upside of 53.95%. Competitively the average price target of Immunomedics Inc. is $24.5, which is potential 88.32% upside. The information presented earlier suggests that Immunomedics Inc. looks more robust than Apellis Pharmaceuticals Inc. as far as analyst view.

Institutional and Insider Ownership

Institutional investors held 66.1% of Apellis Pharmaceuticals Inc. shares and 95.3% of Immunomedics Inc. shares. Insiders held roughly 1.6% of Apellis Pharmaceuticals Inc.’s shares. Comparatively, 7.19% are Immunomedics Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Apellis Pharmaceuticals Inc. -3.62% 9.83% 49.36% 105.82% 57.53% 111.75%
Immunomedics Inc. -2.06% 4.98% -1.34% -1.4% -34.91% 3.36%

For the past year Apellis Pharmaceuticals Inc. was more bullish than Immunomedics Inc.


Apellis Pharmaceuticals Inc. beats Immunomedics Inc. on 6 of the 8 factors.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.